This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
Recruiting
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation - CA239-0010
Updated:
4 October, 2024
|
ClinicalTrials.gov
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Cohort A* (closed): Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (squamous or nonsquamous) KRASG12C mutation and histologically confirmed PD-L1 TPS ≥1%. - Cohort C: Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (non-squamous only) KRASG12C mutation and histologically confirmed PD-L1 TPS < 50% AND previously completed 4 cycles of standard-of-care platinum based induction chemotherapy with pembrolizumab AND experienced stable disease, partial response, or complete response per investigator's assessment after 4 cycles OR if patients received <4 cycles of a platinum-based induction, was stopped early due to intolerable toxicity - Cohort E: Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (non-squamous only) KRASG12C mutation and histologically confirmed PD-L1 TPS < 50% - Presence of measurable disease per RECIST v1.1 Exclusion Criteria: - All Cohorts: Any prior therapy targeting KRASG12C mutation in any setting - Cohorts A & E: Prior systemic therapy for locally advanced or metastatic NSCLC, including chemotherapy, immune checkpoint inhibitor therapy or chemoimmunotherapy (note: prior systemic therapy or chemoradiation given in the adjuvant or neoadjuvant setting are allowed if last dose of prior systemic treatment was >1 year prior to first dose of study treatment) - Cohort C: received maintenance therapy (e.g, pembrolizumab and/or pemetrexed following completion of 4-6 cycles of a platinum-based regimen administered in the first-line setting - Radiation to the lung > 30 Gy within 6 months prior to first dose of study treatment - Active brain metastases
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
466-SE-2100058